by Market Overview:
Buprenorphine is a partial opioid agonist used to treat opioid addiction and pain management. It is available in several formulations like sublingual tablets, buccal films, implants and injections. The sublingual tablets are the most commonly used formulation for opioid dependence treatment. Generic formulations are also available which has increased the accessibility and affordability of buprenorphine treatment.
Market Dynamics:
One of the major drivers for the growth of buprenorphine market is increasing prevalence of opioid addiction worldwide. According to World Drug Report 2021 by United Nations Office on Drugs and Crime, around 275 million people worldwide used drugs and 36 million people suffered from drug use disorders in 2020. North America region has the highest prevalence of opioid use disorders, which is driving the demand for buprenorphine drugs. Second driver is the approval and launch of new buprenorphine formulations like implants, injections and films that offers convenient dosage options and improves treatment compliance.
Segment Analysis
The Buprenorphine Market Demandis dominated by the Sublingual film sub segment. Buprenorphine is primarily used to treat opioid addiction and dependence. The sublingual film formulation of Buprenorphine provides a convenient non-injectable mode of drug delivery and rapid drug absorption through sublingual blood vessels. This eliminates the need for daily supervised administration by healthcare professionals. The sublingual film is simply placed under the tongue and allows for discreet self administration of the drug. As a result of its convenience of use, the sublingual film sub segment accounts for over 50% of the overall Buprenorphine market.
PEST Analysis
Political: Regulations around opioid use and addiction are being tightened globally. However, drugs like Buprenorphine that aid medication-assisted treatment for opioid use disorder are being encouraged and supported through favorable policies.
Economic: The economic cost of the ongoing opioid crisis has been estimated to be over $1 trillion annually in the US alone. Treating opioid addiction in a cost-effective manner provides significant savings to the healthcare system and national economy.
Social: Opioid overdose deaths have reached epidemic levels creating increased social awareness and reducing the stigma around medication-assisted treatment. More people are seeking treatment options like Buprenorphine.
Technological: Advancements in drug delivery technologies have led to the development of user-friendly formulations like sublingual films and implants that aid long-term patient compliance in medication-assisted treatment.
Key Takeaways
The global Buprenorphine market is expected to witness high growth, exhibiting 14% CAGR over the forecast period 2023 to 2030, due to increasing prevalence of opioid use disorder worldwide. The market size is estimated to reach US$ XX Mn by 2030 from an estimated US$ 5526.99 Mn in 2023.
North America dominated the global market in 2023 with over 50% market share owing to rising rates of prescription opioid abuse and high adoption of evidence-based medication-assisted treatment protocols using Buprenorphine in the US. Europe was the second largest regional market supported by initiatives to scale up opioid substitution therapy programs across countries.
Key players operating in the Buprenorphine market are Siegfried, Sanofi, Johnson Matthey, Mallinckrodt, Noramco, Unichem Laboratories, Arevipharma GmbH, Resonance-labs, Sun Pharmaceutical Industries Ltd., Rusan Pharma, Micro Orgo Chem, and Faran Shimi Pharmaceutical Co. Major players are focusing on expanding manufacturing capacities and new product launches to strengthen their market position. Partnerships between device innovators and pharmaceutical companies have also gained significance.
Note:
- Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
